ASTRAZENECA PLC CEDEAR EACH REP 0.5 ADR USD0.25

AstraZeneca's £450 million investment in UK vaccine R&D is on hold amid talks with the government over possible incentives.

AstraZeneca's shares were down nearly 2% following the release of its quarterly results.

AstraZeneca's CFO stated the firm may pursue share buybacks due to recent price changes. The CEO noted it's too soon to evaluate the investigation's effect on the company's future in China.